TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03202004
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream will be provided in tubes labeled in compliance with country requirements.
Study: NCT02677090
Drug: Dose 1 - Promitor®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02677090
Drug: Dose 2 - Promitor®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02677090
Drug: Dose 3 - Promitor®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00514410
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
Study: NCT00514410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once a day for three months
Study: NCT00952094
Drug: KRN1493
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
Study: NCT00028756
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00028756
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03613207
Drug: Oraqix® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
Study: NCT01034410
Drug: AS1411
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1411 40mg/kg/day or AS1411 80mg/kg/day
Study: NCT00808288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, inhaled, dry powder, placebo, OD
Study: NCT01870128
Drug: Combination Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
Study: NCT01870128
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 15 to 25 mg PO per week
Study: NCT01870128
Drug: Combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
Study: NCT00080847
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00080847
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00494494
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical antibiotic for 10 days plus topical corticosteroids for 1 month
Study: NCT00494494
Drug: nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
Study: NCT05429450
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three periocular injections of methotrexate at week 0, week 3 and week 6.
Study: NCT01664143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of placebo
Study: NCT01664143
Drug: RO5508887
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of RO5508887
Study: NCT01790464
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03592121
Drug: AB-101
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply approximately 1 hour prior to sexual activity
Study: NCT03592121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply approximately 1 hour prior to sexual activity
Study: NCT00004412
Drug: Arginine Butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
Study: NCT03037788
Drug: WO3979
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT04354428
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
Study: NCT03037788
Drug: WO3970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT03037788
Drug: WO3992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT03037788
Drug: Placebo (WO3988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT00876304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules every 12 hours for 10 days
Study: NCT04354428
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
Study: NCT02149342
Drug: Hexylaminolaevulinate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
Study: NCT02149342
Drug: Methylaminolaevulinate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL 16% is used as photosensitizer for daylight-PDT
Study: NCT01462357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
Study: NCT01106456
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
Study: NCT00113737
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04354428
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants in a household will receive folic acid and an additional intervention drug
Study: NCT04292730
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT02865031
Drug: Decorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection following ocular trauma to prevent scar tissue formation.
Study: NCT02582099
Drug: Gentamicin nasal irrigation
Normalized name: gentamicin Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal wash with gentamicin solution
Study: NCT01226719
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2, 2-hour IV infusion every 2 weeks
Study: NCT00768729
Drug: MMF or Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
Study: NCT01684462
Drug: 0.9 % Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
Study: NCT02028494
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two dosages comparison
Study: NCT01574703
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All dosing to have taken place per study A3051123
Study: NCT01639027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
Study: NCT00157833
Drug: Artekin / Coartemther
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01831232
Drug: pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01607983
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 parts per million (ppm) of inhaled nitric oxide
Study: NCT03765294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet for oral use
Study: NCT01563068
Drug: Calcipotriene 0.005% Foam
Normalized name: CALCIPOTRIENE 0.005% FOAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application applied twice a day for 15 days
Study: NCT01880307
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00360074
Drug: Thyroxin, Triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00308711
Drug: Dinoprostone vaginal insert (Cervidil)
Normalized name: dinoprostone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Study: NCT02167256
Drug: AZD0530 125mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
Study: NCT02167256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of patients will receive placebo treatment for the duration of the study.
Study: NCT01880307
Drug: Prednisolon
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03470337
Drug: Phlogenzym
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain / Trypsin / Rutoside
Study: NCT01666223
Drug: Chenodeoxycholic Acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
Study: NCT01666223
Drug: Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg
Normalized name: colesevelam hydrochloride 3750 MG
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
Study: NCT03467425
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
Study: NCT03467425
Drug: Inhaled Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid (ICS) as prescribed by the physician.
Study: NCT03467425
Drug: COPD rescue medications
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medications for COPD will be prescribed and obtained according to usual practice.
Study: NCT04044417
Drug: curcumin simvastatin paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
Study: NCT04044417
Drug: EDTA root conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
Study: NCT01313429
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
Study: NCT01313429
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
Study: NCT00712296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 6 capsules twice a day
Study: NCT01176552
Drug: GM-CSF, IFN alpha and IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
Study: NCT04150224
Drug: PBTZ169 640 mg OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two administrations once a day with a wash-out period: food effect
Study: NCT04150224
Drug: PBTZ169 640 mg BiD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day fasted; 1 day of administration
Study: NCT04150224
Drug: PBTZ169 1280 mg MD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day after meal, 14 doses
Study: NCT00569686
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03788733
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 time a day for 8 weeks
Study: NCT03788733
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 time a day for 8 weeks
Study: NCT00352612
Drug: clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
Study: NCT01321801
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative administration of a matching placebo
Study: NCT03597516
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for reconstitution for oral administration
Study: NCT01330758
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg AZD8931 wet granulation tablet formulation
Study: NCT01330758
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg AZD8931 roller compacted tablet formulation
Study: NCT01356433
Drug: oral vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Study: NCT01356433
Drug: oral vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Study: NCT00701129
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered subcutaneously.
Study: NCT02412631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for lorcaserin
Study: NCT02932891
Drug: DSXS topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment
Study: NCT04181346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02177266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will match the study drug.
Study: NCT03304899
Drug: RiaSTAP Injectable Product
Normalized name: RiaSTAP Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))
Study: NCT01367808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Study: NCT03364049
Drug: MK-7162
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT04038489
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
Study: NCT04038489
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
Study: NCT00546715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, Single Dose
Study: NCT00755079
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
Study: NCT01369875
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
Study: NCT00630045
Drug: neoadjuvant chemotherapy with oxaliplatin and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
Study: NCT01993108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo one hour before fMRI scanning.
Study: NCT04341480
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy for individual tumor type.
Study: NCT00577122
Drug: Medroxyprogesterone with Cyclophosphamide + Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
Study: NCT01340976
Drug: LY2787106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT02953821
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
Study: NCT00782210
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
Study: NCT04447092
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
Study: NCT04447092
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
Study: NCT00654381
Drug: BI 1356 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03641573
Drug: [14C] ASN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\] ASN002
Study: NCT00628550
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
Study: NCT00774098
Drug: dextrose 10% (D10W ®) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Started at 8pm the day before surgery until the procedure begins
Study: NCT03050905
Drug: VEKIRAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)
Study: NCT00251394
Drug: 1018 ISS
Normalized name: 1018 ISS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
Study: NCT01834404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills matched the study drug in appearance for the 2 dose levels.
Study: NCT00754247
Drug: Cetearyl alcohol lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
Study: NCT03018353
Drug: Patients receiving Sof/Vel (Epclusa) and Navigation services
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
Study: NCT01470469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral dosing in the evening for 12 weeks.
Study: NCT03242499
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin 80mg or placebo use for 48 weeks.
Study: NCT03242499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 48 weeks
Study: NCT00482391
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00482391
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02611492
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
Study: NCT02611492
Drug: 6 Mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 per os, D1 to D14, interphase
Study: NCT04498962
Drug: Danzhu Fuyuan Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.